GB202018468D0 - New therapy - Google Patents

New therapy

Info

Publication number
GB202018468D0
GB202018468D0 GBGB2018468.5A GB202018468A GB202018468D0 GB 202018468 D0 GB202018468 D0 GB 202018468D0 GB 202018468 A GB202018468 A GB 202018468A GB 202018468 D0 GB202018468 D0 GB 202018468D0
Authority
GB
United Kingdom
Prior art keywords
new therapy
therapy
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2018468.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Index Pharmaceuticals AB
Original Assignee
Index Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals AB filed Critical Index Pharmaceuticals AB
Priority to GBGB2018468.5A priority Critical patent/GB202018468D0/en
Publication of GB202018468D0 publication Critical patent/GB202018468D0/en
Priority to AU2021386281A priority patent/AU2021386281A1/en
Priority to CN202180091789.4A priority patent/CN116867499A/en
Priority to JP2023531702A priority patent/JP2023553336A/en
Priority to PCT/EP2021/082627 priority patent/WO2022112224A1/en
Priority to CA3202097A priority patent/CA3202097A1/en
Priority to EP21835160.9A priority patent/EP4251270A1/en
Priority to KR1020237020455A priority patent/KR20230112664A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB2018468.5A 2020-11-24 2020-11-24 New therapy Ceased GB202018468D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2018468.5A GB202018468D0 (en) 2020-11-24 2020-11-24 New therapy
AU2021386281A AU2021386281A1 (en) 2020-11-24 2021-11-23 Cobitolimod dosage for self-administration
CN202180091789.4A CN116867499A (en) 2020-11-24 2021-11-23 Comparable tolmod dosage for self-administration
JP2023531702A JP2023553336A (en) 2020-11-24 2021-11-23 Cobitolimod dosage for self-administration
PCT/EP2021/082627 WO2022112224A1 (en) 2020-11-24 2021-11-23 Cobitolimod dosage for self-administration
CA3202097A CA3202097A1 (en) 2020-11-24 2021-11-23 Cobitolimod dosage for self-administration
EP21835160.9A EP4251270A1 (en) 2020-11-24 2021-11-23 Cobitolimod dosage for self-administration
KR1020237020455A KR20230112664A (en) 2020-11-24 2021-11-23 Cobitolimod Dosage for Self-Administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2018468.5A GB202018468D0 (en) 2020-11-24 2020-11-24 New therapy

Publications (1)

Publication Number Publication Date
GB202018468D0 true GB202018468D0 (en) 2021-01-06

Family

ID=74046798

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2018468.5A Ceased GB202018468D0 (en) 2020-11-24 2020-11-24 New therapy

Country Status (8)

Country Link
EP (1) EP4251270A1 (en)
JP (1) JP2023553336A (en)
KR (1) KR20230112664A (en)
CN (1) CN116867499A (en)
AU (1) AU2021386281A1 (en)
CA (1) CA3202097A1 (en)
GB (1) GB202018468D0 (en)
WO (1) WO2022112224A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy

Also Published As

Publication number Publication date
WO2022112224A1 (en) 2022-06-02
KR20230112664A (en) 2023-07-27
EP4251270A1 (en) 2023-10-04
AU2021386281A9 (en) 2024-02-08
AU2021386281A1 (en) 2023-07-13
CA3202097A1 (en) 2022-06-02
CN116867499A (en) 2023-10-10
JP2023553336A (en) 2023-12-21

Similar Documents

Publication Publication Date Title
GB202001980D0 (en) Therapeutic mentods
GB202006960D0 (en) Therapeutic
GB201912191D0 (en) New therapy
GB202108303D0 (en) Therapy
GB202111288D0 (en) Combination therapy
GB202004189D0 (en) Combination therapy
GB202113079D0 (en) New therapy
GB202018468D0 (en) New therapy
GB202117706D0 (en) Therapy
GB202111035D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202103164D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy
GB202017598D0 (en) Therapy
GB202017554D0 (en) Therapy
GB202015780D0 (en) Therapy
GB202015778D0 (en) Therapy
GB202013824D0 (en) PeptiBAC therapy
GB202013834D0 (en) PeptiVAX therapy
GB202009039D0 (en) Therapy
GB202008031D0 (en) Therapy
GB202004629D0 (en) Therapy
GB202004013D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)